回顾性分析疏风解毒胶囊联合西医治疗普通型新型冠状病毒肺炎患者的临床疗效

Clinical Efficacy of Shufeng Jiedu Capsule Combined with Western Medicine in Treatment of Common COVID-19 Patients by Retrospective Analysis

目的:分析联合应用疏风解毒胶囊治疗普通型新型冠状病毒肺炎(coronavirus disease-2019,COVID-19)患者的临床疗效。方法:采取倾向性评分匹配研究法,选择2020年1月27日至2020年3月5日在武汉市第三医院就诊的符合普通型COVID-19患者的临床资料,符合纳排标准的疏风解毒胶囊联合常规治疗患者34例为治疗组,倾向性配对1∶1,常规治疗患者34例为对照组。比较两组主要症状(发热、咳嗽、咯痰、乏力)的消失率、消失天数、有效率,其他症状消失率,治疗7 d前后的实验室指标差异,肺部计算机断层扫描(CT)有效率,转重率及总住院时间等。结果:两组基线资料比较,差异无统计学意义,具有可比性。治疗7 d,治疗组咳嗽、咯痰、乏力、胸闷、喘气的消失率高于对照组(P<0. 05);治疗组主要症状平均消失天数明显少于对照组(P<0. 05);治疗组主要症状治疗有效率明显高于对照组(P<0. 05);治疗组有8. 8%(3/34)的患者转重型,对照组有26. 5%(9/34)的患者转重型,差异无统计学意义;治疗7 d,与本组治疗前比较,治疗组淋巴细胞明显上升(P<0. 05),C反应蛋白,降钙素原,D-二聚体水平明显下降(P<0. 05);对照组淋巴细胞明显上升(P<0. 05),C反应蛋白明显下降(P<0. 05);治疗组肺部CT改善率91. 2%(31/34),明显高于对照组70. 6%(24/34,P<0. 05);两组患者治疗后均痊愈出院,治疗组平均住院时间(15. 53±2. 63)d,对照组平均住院时间(16. 35±4. 98)d,差异无统计学意义;治疗组无不良事件,对照组出现了3例不良事件。结论:联合应用疏风解毒胶囊能明显改善普通型COVID-19患者的咳嗽、咳痰、乏力、胸闷、喘气的临床症状,提高主要症状有效率,调控相关外周血炎症指标的表达,促进肺部炎症吸收,提高治愈率,提示疏风解毒胶囊可以有效地应用于普通型COVID-19患者治疗中。

Objective: To analyze the clinical efficacy of Shufeng Jiedu Capsule(SFJD) capsule combined with western medicine in the treatment of common coronavirus disease-2019(COVID-19). Method:By the usage propensity score matching,the clinical data of COVID-19 patients with common COVID-19 admitted to Wuhan third hospital from January 27,2020(solstice)to March 5,2020,were screened out. Thirtyfour patients with SFJD capsule combined with conventional therapy according to the inclusion and exclusion criteria were enrolled in treatment group,and 34 patients treated with conventional therapy were enrolled in control group. The disappearance rate of main symptoms(fever,cough,expectoration and fatigue),days of syndrome disappearance,effective rate and disappearance rate of other symptoms,laboratory indexes before treatment and after 7 days ′treatment,effective rate of computed tomography(CT)of the lungs,rate of COVID-19 severe transformation and hospitalization time between the two groups were compared. Result: The baseline data between the two groups showed no statistically significant difference,and was comparable. After 7 days of treatment,the symptom disappearance rate of cough,sputum,fatigue,chest tightness and panting in treatment group was significantly higher than that in control group(P<0. 05). The average days of disappearance of main symptoms in treatment group was significantly less than that in control group(P<0. 05). The effective rate of main symptom was significantly higher than control group(P<0. 05). In treatment group,8. 8%(3/34)of the patients were transferred to severe disease,while 26. 5%(9/34)of the patients in control group were transferred to severe disease,with statistically significant differences. After treatment for 7 days,lymphocytes in treatment group significantly increased(P<0. 05),C-reactive protein significantly decreased(P<0. 05),procalcitonin level significantly decreased(P<0. 05), and D-dimer level significantly decreased(P<0. 05), while lymphocytes in control group significantly increased(P<0. 05),and c-reactive protein significantly decreased(P<0. 05). The improvement rate of pulmonary CT in treatment group was 91. 2%(31/34),which was significantly higher than 70. 6%(24/34)in control group(P<0. 05). After treatment,both groups were cured and discharged,the average length of stay in treatment group was(15. 53±2. 63)d,which was(16. 35±4. 98)d in control group,with no statistically significant difference. No adverse events occurred in treatment group,but3 cases occurred in control group. Conclusion: SFJD capsule combined with western medicine can significantly improve the clinical symptoms of normal COVID-19 patients,such as cough,sputum,fatigue,chest distress and shortness of breath,alleviate the main symptoms effectively,regulate the expressions of relevant peripheral inflammation,promote the absorption of lung inflammation,and improve the cure rate,which indicates that SFJD capsule can be effectively in the treatment of patients with common COVID-19.